Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Status:
RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.